This document details a new patent application, US20260085330A1, filed by Karyocreate with the USPTO on September 8, 2023. The application describes a novel fusion protein comprising a mutated kinetochore protein and dCas9, used with guide RNAs to target kinetochore assembly on a centromere. This mechanism interferes with chromosome segregation, leading to cells acquiring an aneuploidy karyotype. Expression vectors for these components and their use in producing aneuploidy are also covered.

This is a patent application, not a rule or guidance document, and therefore carries no immediate compliance obligations for regulated entities. However, it signifies potential future intellectual property developments in CRISPR technology and its applications in areas such as drug development or genetic research. Companies operating in the biotechnology and pharmaceutical sectors should be aware of this filing as it may impact future research and development strategies or licensing opportunities.